Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study (Q40984232)

25 September 2017

title

Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study (English)

1 reference

25 September 2017

1 reference

34

Masashi Mizokami

1 reference

25 September 2017

2

Yasuhito Tanaka

1 reference

25 September 2017

30

Eiji Tanaka

1 reference

25 September 2017

35

Ryuzo Ueda

1 reference

25 September 2017

1

Shigeru Kusumoto

1 reference

25 September 2017

3

Ritsuro Suzuki

1 reference

25 September 2017

5

Masanobu Nakata

1 reference

25 September 2017

7

Noriyasu Fukushima

1 reference

25 September 2017

8

Takuya Fukushima

1 reference

25 September 2017

9

Yukiyoshi Moriuchi

1 reference

25 September 2017

10

Kuniaki Itoh

1 reference

25 September 2017

11

Kisato Nosaka

1 reference

25 September 2017

12

Ilseung Choi

1 reference

25 September 2017

13

Masashi Sawa

1 reference

25 September 2017

14

Rumiko Okamoto

1 reference

25 September 2017

15

Hideki Tsujimura

1 reference

25 September 2017

16

Toshiki Uchida

1 reference

25 September 2017

18

Masataka Okamoto

1 reference

25 September 2017

20

Isamu Sugiura

1 reference

25 September 2017

21

Yasushi Onishi

1 reference

25 September 2017

22

Mika Kohri

1 reference

25 September 2017

23

Shinichiro Yoshida

1 reference

25 September 2017

24

Rika Sakai

1 reference

25 September 2017

25

Minoru Kojima

1 reference

25 September 2017

28

Dai Maruyama

1 reference

25 September 2017

29

Yoshiko Atsuta

1 reference

25 September 2017

31

Takayo Suzuki

1 reference

25 September 2017

33

Michinori Ogura

1 reference

25 September 2017

Takashi Watanabe

4

1 reference

25 September 2017

Hirotaka Takasaki

6

1 reference

25 September 2017

Sachiko Suzuki

17

1 reference

25 September 2017

Tsutomu Takahashi

19

1 reference

25 September 2017

Hiroyuki Takahashi

26

1 reference

25 September 2017

Akihiro Tomita

27

1 reference

25 September 2017

Tomohiro Kinoshita

32

1 reference

25 September 2017

language of work or name

English

0 references

publication date

1 May 2015

1 reference

Clinical Infectious Diseases

25 September 2017

published in

1 reference

25 September 2017

volume

61

1 reference

25 September 2017

issue

5

1 reference

25 September 2017

page(s)

719-729

1 reference

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.

25 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV344

Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV344

Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV344

Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV344

Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV344

FDA: Increased HBV reactivation risk with ofatumumab or rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV344

Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV344

Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV344

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV344

Reactivation of hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV344

American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV344

Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV344

Reactivation of hepatitis B virus in HBsAg-negative patients with multiple myeloma: two case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV344

Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV344

Fully automated quantitation of hepatitis B virus (HBV) DNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV344

Hepatitis B virus (HBV) genotype determination by the COBAS AmpliPrep/COBAS TaqMan HBV Test, v2.0 in serum and plasma matrices

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV344

Development and public release of a comprehensive hepatitis virus database

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV344

Performance of the DiaSorin LIAISON(®) anti-HBs II for the detection of hepatitis B surface antibodies: comparison with the Abbott Architect anti-HBs assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV344

Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV344

Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV344

Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV344

Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV344

Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV344

Fatal hepatitis B reactivation treated with entecavir in an isolated anti-HBs positive lymphoma patient: a case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV344

Baseline hepatitis B vaccination coverage among persons with diabetes before implementing a U.S. recommendation for vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV344

Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV344

Is antiviral prophylaxis necessary to prevent hepatitis B virus (HBV) reactivation in patients with HBV-resolved infection receiving rituximab-containing chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV344

21 January 2018

Identifiers

DOI

10.1093/CID/CIV344

1 reference

25 September 2017

1 reference